Tvardi Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital analyst Christopher Liu initiated coverage of Tvardi Therapeutics (TVRD) with a Buy rating and $42 price target Tvardi is a clinical-stage biotechnology company focused on developing novel therapies in fibrotic lung disease and oncology, the analyst tells investors in a research note. The firm believes the company’s STAT3 inhibitor, TTI-101, could be a “significant value driver” for shares approaching the un-blinding of the Phase 2 data in idiopathic pulmonary fibrosis later this year. Lucid sees its peak sales estimate of $2.8B by 2039 in IPF as “relatively conservative.”